ClinicalTrials.gg
SuspendedNCT05689710Updated Dec 30, 2025

The Effects of Inositol on Glucose Metabolism in Patients With Metabolic Syndrome at Risk of Cardiac Fibrosis

An interventional study of Inositol and alpha-lactalbumin in Metabolic Syndrome and Cardiac Fibrosis, sponsored by Lo.Li.Pharma s.r.l. Suspended at 1 site in Italy. Per ClinicalTrials.gov, last updated 2025-12-30.

Sponsored by Lo.Li.Pharma s.r.l · Not applicable, Interventional, and Supportive care

How we know

Why this study was suspended
Difficulties in enrollment and patient compliance

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 95 studies in Metabolic Syndrome with a site in Italy — 16 open to participants now, 18 under way, none of them phase 3. Metabolic Syndrome · Italy.

Planned enrollment
54th of 62
30 · median 71
Started
2022
with 9 others
No phase
38 of 95
8 open now
Registered
70th of 95
by date

Among the 95 studies in Metabolic Syndrome with a site in Italy, this one is the 54th largest by planned enrollment of the 62 interventional ones that give a count, is one of 10 that started in 2022, is one of 38 with no phase, and was the 70th registered.

Metabolic Syndrome

2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

16 of the 95 studies in Metabolic Syndrome with a site in Italy are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 95 studies in Metabolic Syndrome with a site in Italy, or all of them as a file.
02

Study summary

The study aims to evaluate the effects of an oral supplementation based on inositols and alpha-lactalbumin on principals metabolic parameters in patients with metabolic syndrome at risk of cardiac fibrosis

03

Conditions studied

  • Metabolic Syndrome
  • Cardiac Fibrosis

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

At least 3 of the following inclusion criteria:

  • triglycerides levels ≥ 150 mg/dL
  • HDL ≤ 40 mg/dL
  • Fasting glycemia > 100 mg/dL \<126 mg/dl
  • Systolic Pressure ≥ 130 mmHg or Diastolic pressure ≥ 85 mmHg
  • Hip circumference > 102 cm in men or 88 cm in women
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • No intervention
    No intervention
  • Experimental
    Experimental

    Dietary Supplement with inositols and alpha-lactalbumin

    Dietary Supplement: Inositol and alpha-lactalbumin

Interventions

06

What researchers measure

Primary outcomes

  1. Body weight

    Time frame: Four time points: changes in body weight (kg) from the baseline to 30, 90, 180 days

Secondary outcomes

  1. Tryglicerides

    Plasmatic levels of tryglicerides

    Time frame: Four time points: changes in blood levels of tryglycerides from the baseline to 30, 90, 180 days

  2. Hypertension

    sphygmomanometer

    Time frame: Four time points: changes in values of systolic and diastolic blood pressure from the baseline to 30, 90, 180 days

07

Study locations

1 site
  • UOC Medicina Interna e Nefrologia P.O. AQ
    L’Aquila, Italy
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2022 (actual). Primary completion is estimated for Jan 2026, 37 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2022
First posted
Jan 19, 2023
StartActual
Dec 23, 2022
Primary completionEst.
Jan 2026
CompletionEst.
Jan 2026
Last update
Dec 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05689710
Lead sponsor
Lo.Li.Pharma s.r.l
Responsible party
Sponsor
First posted
Jan 19, 2023
Start date
Dec 23, 2022
Primary completion
Jan 2026 (estimated)
Completion
Jan 2026 (estimated)
Last update
Dec 30, 2025

Study contacts

Davide Grassi, MD
principal investigator · UOC Medicina Interna e Nefrologia P.O. AQ
Claudio Ferri, MD
principal investigator · UOC Medicina Interna e Nefrologia P.O. AQ

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Inositol · Lactalbumin

Start the discussion